Abstract
Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin’s lymphoma (NHL).[1][1]–[3][2] Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5–10% of the patients and carries a dismal prognosis.[4][3],[5][4] Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.[6][5]–[8][6] We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies. [1]: #ref-1 [2]: #ref-3 [3]: #ref-4 [4]: #ref-5 [5]: #ref-6 [6]: #ref-8

This publication has 10 references indexed in Scilit: